Poly(acrylamido) PEG-alternatives Enhance mRNA-LNP Efficacy in Immune Cells and Evade anti-PEG Antibodies During Repeated Dosing

This study introduces a new family of poly(acrylamido) lipid-based PEG alternatives that significantly enhance mRNA-LNP transfection efficacy in immune cells and lymphoid tissues while successfully evading anti-PEG antibodies to restore therapeutic effectiveness during repeated dosing.

The Gist

The Big Problem: The "Velcro" Effect

Imagine you are trying to deliver a very important letter (mRNA) to a specific house in a neighborhood (your cells). To protect the letter during the journey, you put it inside a sturdy, invisible bubble (a Lipid Nanoparticle or LNP).

For years, scientists have coated these bubbles with a special material called PEG (Polyethylene Glycol). Think of PEG as a layer of slippery, non-stick Teflon. Its job is to stop the body's security guards (immune cells and proteins) from grabbing onto the bubble, sticking to it, and throwing it out of the system before it reaches the target.

However, there's a catch: Because PEG is used in so many things (lotions, toothpaste, other medicines), many people have already developed antibodies against it. It's like the neighborhood security guards have learned to recognize the "Teflon" pattern. When they see it, they grab the bubble immediately, destroy it, and kick it out of the body. This is called the "Accelerated Blood Clearance" effect.

If you need to give a second dose of medicine (like a booster shot), the body recognizes the Teflon coating even faster, making the second dose useless. This is a major problem for future treatments.

The Solution: A New "Disguise"

The researchers in this paper asked: "What if we could replace the Teflon with a different material that looks and feels just as slippery to the body, but is chemically different enough that the security guards don't recognize it?"

They created a new family of materials called PAM-lipids (Poly(acrylamido) lipids). Think of PAMs as a new, custom-made camouflage suit. It does the exact same job as the Teflon (keeping the bubble safe and smooth), but the security guards have never seen this pattern before, so they ignore it.

What They Discovered

1. The "Hat" Matters (End Groups)
The researchers found that the chemical structure of the PAM matters, but the very tip of the molecule (the "end group") is surprisingly important.

• Analogy: Imagine the PAM molecule is a long coat. The researchers found that if the coat has a heavy, greasy hood (a hydrophobic end group), it makes the bubble clump together and fall apart. But if they swap the greasy hood for a clean, dry one (a hydrophilic -H or -OH end group), the bubble stays perfectly round and stable.
• Result: They found specific PAM recipes that made bubbles smaller and more uniform than the old PEG ones.

2. Better Delivery to the "Command Centers"
The goal of mRNA vaccines is often to teach the immune system. The immune system's "command centers" are the lymph nodes and specific cells like dendritic cells.

• The Finding: The new PAM bubbles didn't just survive longer; they were actually better at getting into these command centers.
• Analogy: If PEG bubbles were like a delivery truck that dropped the package at the front door, the PAM bubbles were like a delivery truck that knew the secret back entrance. In lab tests, PAM bubbles were up to 120 times more effective at getting into immune cells than the old PEG bubbles. In live mice, they were 5 times better at delivering the message to the lymph nodes.

3. The "Reset Button" for Repeated Doses
This is the most exciting part. The researchers tested what happens when you give the same animal multiple doses.

• The PEG Scenario: Dose 1 works. Dose 2 fails because the body has antibodies against PEG and destroys the bubbles immediately.
• The PAM Scenario: The researchers gave the mice three doses of the old PEG bubbles (building up antibodies) and then, for the fourth dose, they switched to the new PAM bubbles.
• The Result: The body's antibodies, which were ready to attack the PEG, didn't recognize the PAM. The fourth dose worked perfectly, recovering 100% of the lost effectiveness. It was like changing the disguise at the last second, fooling the security guards completely.

4. Staying Stable in the Fridge
Medicines need to be stored in fridges. The researchers checked if these new bubbles would fall apart after sitting in the fridge for weeks.

• The Finding: The PAM bubbles were just as stable as the PEG bubbles. They didn't clump together or leak their cargo. This means they are ready for real-world use without needing special freezing equipment.

Why This Matters

This paper isn't just about making one new drug; it's about creating a new toolbox.

• Diversity is Key: Just as antibiotics need to be varied to fight different bacteria, we need a variety of "stealth coatings" to fight different immune responses.
• The Future: By using PAMs, scientists can now design mRNA therapies that can be given repeatedly (boosters, chronic treatments) without the body rejecting them. It solves the problem of "anti-PEG antibodies" and opens the door for more effective cancer treatments, gene therapies, and vaccines.

In a nutshell: The researchers found a new "slippery coat" (PAM) that protects medicine better than the old one (PEG), gets it to the right cells faster, and—most importantly—can trick the body's immune system so that repeat doses actually work.

Technical Summary

1. Problem Statement

Messenger RNA lipid nanoparticles (mRNA-LNPs) have revolutionized vaccine development (e.g., COVID-19 vaccines) and are being explored for cancer immunotherapy and protein replacement. However, current clinical formulations rely heavily on poly(ethylene glycol)-lipids (PEG-lipids) to stabilize the particles and prevent aggregation.

• The Core Issue: The widespread use of PEG in pharmaceuticals and cosmetics has led to a high prevalence of pre-existing anti-PEG antibodies in the human population (~72% prior to the pandemic, rising significantly post-vaccination).
• Consequences: Upon repeated dosing, these antibodies cause:
  1. Accelerated Blood Clearance (ABC): Rapid removal of LNPs by the liver (Kupffer cells), reducing therapeutic efficacy.
  2. Adverse Reactions: Increased risk of pseudo-allergic responses (CARPA).
  3. Instability: Antibody binding can destabilize LNPs, causing premature cargo leakage.
• Current Limitations: Existing PEG alternatives (e.g., poly(oxazoline), poly(sarcosine)) are often developed on a "one-by-one" basis and may still trigger immune responses. There is an urgent need for a versatile family of chemically diverse PEG alternatives that can evade anti-PEG antibodies while maintaining or enhancing LNP performance.

2. Methodology

The authors developed a library of N-substituted poly(acrylamido) lipids (PAM-lipids) as direct replacements for PEG-lipids.

• Synthesis Strategy:
  • Utilized Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization to synthesize PAM-lipids with precise control over molecular weight and dispersity.
  • Used a DMG (dimyristoyl glycerol) functionalized chain transfer agent (CTA) to attach a lipid tail, ensuring integration into the LNP bilayer.
  • Generated a library of 30 unique PAM-lipids varying by:
    • Monomer Chemistry: 5 different acrylamide monomers (e.g., DMA, NAM, HEA, HMA, MOMAM).
    • Chain Length: Degree of Polymerization (DP) of 20 (~2 kDa) and 60.
    • End-Groups: Modified the trithiocarbonate end-group to -H, -OH, or retained the native -S₃C₅H₉.
• Formulation:
  • Replaced DMG-PEG2k in the standard Moderna SpikeVax™ formulation (SM102 ionizable lipid, DSPC, Cholesterol, DMG-PEG/PAM at 50:10:38.5:1.5 molar ratio).
  • Encapsulated mRNA encoding Firefly Luciferase (fLuc), eGFP, or Cy5-tagged mRNA.
• Characterization & Testing:
  • Physicochemical: Dynamic Light Scattering (DLS), Cryo-EM, Small-Angle X-ray/Neutron Scattering (SAXS/SANS).
  • In Vitro: Transfection in DC2.4 dendritic cells and primary Bone Marrow Dendritic Cells (BMDCs) under low and high serum conditions.
  • In Vivo: Intramuscular (IM), Intradermal (ID), and Intravenous (IV) administration in mice (BALB/c and C57BL/6).
  • Immunogenicity: Repeated dosing regimens to induce anti-polymer antibodies; ELISA to measure antibody binding and titers.

3. Key Contributions

1. Discovery of PAM-Lipids: Established a chemically diverse family of PAM-lipids as effective, scalable replacements for PEG-lipids.
2. Structure-Activity Relationship (SAR): Identified that monomer side-group chemistry is the critical factor for evading antibody cross-reactivity, while end-group hydrophilicity (-H or -OH) is essential for forming stable, small-sized LNPs.
3. Efficacy Recovery: Demonstrated for the first time that switching to a PAM-lipid (specifically DMA20-H) in a heterologous dosing regimen can fully recover mRNA expression lost due to anti-PEG antibodies.
4. Enhanced Immune Targeting: Showed that PAM-LNPs significantly outperform PEG-LNPs in transfecting primary immune cells (dendritic cells, macrophages, T-cells) and targeting lymphoid tissues.

4. Key Results

A. Physicochemical Properties

• Size & Stability: PAM-LNPs with hydrophilic end-groups (-H or -OH) formed nanoparticles of ~100–150 nm with low polydispersity (PDI < 0.25), comparable to PEG-LNPs. Hydrophobic end-groups (-S₃C₅H₉) resulted in larger, unstable particles.
• Structure: Cryo-EM and SANS revealed that PAM-LNPs possess a similar "core-shell-bleb" morphology and internal structure to PEG-LNPs, confirming they do not fundamentally alter the LNP architecture.
• Storage: PAM-LNPs maintained colloidal stability and transfection efficacy after 5 weeks of storage at 4°C, comparable to or better than PEG-LNPs.

B. In Vitro Efficacy

• Transfection Boost: In DC2.4 cells and primary BMDCs, specific PAM-LNPs (e.g., DMA20-H, NAM20-H, HEA20-H) showed up to 120-fold higher transfection efficiency in low serum and up to 20-fold in high serum compared to PEG-LNPs.
• Serum Resistance: PAM-LNPs maintained high efficacy in the presence of serum proteins, whereas PEG-free LNPs failed completely, and PEG-LNPs showed reduced uptake.

C. In Vivo Performance

• Tissue Tropism: Following IM and ID administration, PAM-LNPs (specifically DMA20-H) showed 2.5-fold higher mRNA expression in lymph nodes and ~5-fold higher transfection in immune cells (macrophages, T-cells) compared to PEG-LNPs.
• Cellular Uptake: Flow cytometry confirmed increased association and uptake of PAM-LNPs by primary immune cells (BMDCs).

D. Antibody Evasion and Repeat Dosing

• Anti-PEG Evasion: PAM-LNPs did not bind to pre-existing anti-PEG IgM antibodies.
• Heterologous Dosing Recovery: In a repeated dosing study (3 doses of PEG-LNP followed by 1 dose of PAM-LNP):
  • Repeated PEG dosing caused a ~2-fold drop in liver expression due to anti-PEG antibodies.
  • Switching to DMA20-H for the final dose fully recovered hepatic and extrahepatic mRNA expression to levels seen in a single-dose PEG regimen (a 300% increase over the repeated PEG group).
• Cross-Reactivity: While anti-PAM antibodies were generated after repeated PAM dosing, monomer chemistry (e.g., switching from DMA to HEA) was found to be the dominant factor in evading antibody binding, whereas changing the end-group had minimal effect.

5. Significance and Future Outlook

• Next-Generation Therapeutics: This work establishes PAM-lipids not just as a single alternative, but as a versatile platform for designing future mRNA-LNPs. The ability to synthesize diverse monomers allows for a "library" approach to evade specific immune responses.
• Clinical Relevance: The findings directly address the critical barrier of anti-PEG antibodies, enabling safe and effective repeat dosing strategies required for chronic diseases, cancer immunotherapies, and booster vaccines.
• Mechanistic Insight: The study clarifies that side-group chemistry is the primary epitope for antibody recognition, guiding future polymer design.
• Broader Application: Beyond mRNA, this platform could benefit other PEGylated therapeutics (e.g., liposomal chemotherapeutics, PEGylated peptides) susceptible to accelerated blood clearance.

In conclusion, the authors successfully demonstrated that Poly(acrylamido) lipids are superior to PEG-lipids in terms of immune cell transfection, lymphoid targeting, and the ability to evade anti-PEG antibodies, offering a robust solution for the next generation of mRNA-based medicines.